MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02038647
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01990534
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Phase 1
Completed
- Conditions
- Inflammatory Bowel Disease
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01981616
- Locations
- 🇬🇧
ICON Development Solutions, Manchester, United Kingdom
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01953783
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Phase 1
Completed
- Conditions
- Hodgkin LymphomaAnaplastic Large-cell Lymphoma
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01950364
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01939899
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01912222
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
Phase 1
Completed
- Conditions
- Advanced Nonhematologic Malignancies
- Interventions
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01899053
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01898078
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01862328
© Copyright 2025. All Rights Reserved by MedPath